secwatch.observer — SEC 8-K summary
======================================

Issuer:     InfuSystem Holdings, Inc (INFU)
CIK:        0001337013
Form:       8-K
Filed at:   2024-06-12T23:59:59+00:00
Accession:  0001628280-24-027849
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InfuSystem projects 2024 revenue of $134.2M and adjusted EBITDA of $26.5M
-------------------------------------------------------------------------

- 2023 revenue $125.8M (12% CAGR over 5 years); adjusted EBITDA $22.4M.
- Q1 2024 revenue $32.0M; adjusted EBITDA $3.9M (vs. $4.2M in Q1 2023).
- Guidance: 2024 revenue ~$134.2M (high single-digit growth); adjusted EBITDA ~$26.5M (margin 19.7%).
- Patient Services gross margin stable at ~63%; Device Solutions gross margin declined to 31.5% (TTM).
- Capital allocation: $20M share repurchase program; net leverage 1.32x; NOLs $26.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1337013/000162828024027849/0001628280-24-027849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1337013/000162828024027849/infu-20240612.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-027849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer